Stratrix

The decisions that made it

The Gold Rush · Decision Forks
The GLP-1 Supercycle Has One Crack: Two-Thirds of Patients Quit Within a Year.
Semaglutide crossed $29 billion in 2024 and analysts see a $95–$190 billion market by the mid-2030s. But up to 65% of obesity patients stop within 12 months — and the gold rush belongs to whoever solves staying, not starting.
8 min
The GLP-1 Gold Rush — the decisions that defined it | Stratrix